Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 200 Total
BDRX - Biodexa Pharmaceuticals Plc ADR - Stock Price Chart
TickerBDRX [NASD]
CompanyBiodexa Pharmaceuticals Plc ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap1.03MEPS (ttm)-49.74
P/E-EPS this Y99.87%
Forward P/E-EPS next Y12.18%
PEG-EPS past 5Y86.34%
P/S10.27EPS next 5Y89.98%
P/B0.14EPS Q/Q97.12%
Dividend-Sales Q/Q-100.00%
Insider Own-Inst Own1.27%
Insider Trans-Inst Trans0.11%
Short Float-EarningsSep 26/b
Analyst Recom1.00Target Price18.00
Avg Volume1.58M52W Range1.84 - 74.00
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
ALXO - Alx Oncology Holdings Inc - Stock Price Chart
TickerALXO [NASD, RUT]
CompanyAlx Oncology Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap37.75MEPS (ttm)-2.61
P/E-EPS this Y34.84%
Forward P/E-EPS next Y14.36%
PEG-EPS past 5Y-32.29%
P/S-EPS next 5Y22.88%
P/B0.33EPS Q/Q40.49%
Dividend-Sales Q/Q-
Insider Own36.24%Inst Own56.31%
Insider Trans0.06%Inst Trans-3.20%
Short Float17.29%EarningsMar 06/a
Analyst Recom1.57Target Price4.14
Avg Volume1.11M52W Range0.73 - 17.83
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pinto ShellySVP, FINANCE AND CAOFeb 19 '25Sale1.1555063387,352Feb 21 04:25 PM
Pons JaumePRESIDENT & CSOFeb 19 '25Sale1.151,3261,525579,388Feb 21 04:23 PM
Lettmann JasonCHIEF EXECUTIVE OFFICERFeb 19 '25Sale1.152,1592,483170,270Feb 21 04:20 PM
Pinto ShellyInterim CFOJan 06 '25Sale1.802,2213,99887,902Jan 08 04:10 PM
Pinto ShellyInterim CFODec 30 '24Sale1.581,4262,25390,123Jan 02 04:46 PM
MGNX - Macrogenics Inc - Stock Price Chart
TickerMGNX [NASD, RUT]
CompanyMacrogenics Inc
CountryUSA
IndustryBiotechnology
Market Cap125.21MEPS (ttm)-1.07
P/E-EPS this Y-135.20%
Forward P/E-EPS next Y30.30%
PEG-EPS past 5Y19.47%
P/S0.83EPS next 5Y-28.62%
P/B1.08EPS Q/Q66.81%
Dividend-Sales Q/Q80.53%
Insider Own8.07%Inst Own84.48%
Insider Trans-0.01%Inst Trans-4.92%
Short Float8.85%EarningsMar 20/a
Analyst Recom2.29Target Price6.75
Avg Volume584.37K52W Range2.03 - 19.54
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bonvini EzioSr VP, Research & CSOFeb 15 '25Option Exercise0.0016,6650124,414Feb 19 04:31 PM
Karrels JamesSVP, CFO and SecretaryFeb 15 '25Option Exercise0.0014,9980192,591Feb 19 04:29 PM
Koenig ScottPresident and CEOFeb 15 '25Option Exercise0.0042,3290777,415Feb 19 04:28 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 15 '25Option Exercise0.0013,332018,858Feb 19 04:25 PM
Risser Eric BlasiusChief Operating OfficerFeb 15 '25Option Exercise0.0016,665062,422Feb 19 04:24 PM
CHGG - Chegg Inc - Stock Price Chart
TickerCHGG [NYSE, RUT]
CompanyChegg Inc
CountryUSA
IndustryEducation & Training Services
Market Cap75.30MEPS (ttm)-8.13
P/E-EPS this Y-88.00%
Forward P/E1194.00EPS next Y-99.34%
PEG-EPS past 5Y-151.46%
P/S0.12EPS next 5Y-
P/B0.39EPS Q/Q50.04%
Dividend-Sales Q/Q-23.67%
Insider Own7.16%Inst Own77.14%
Insider Trans0.00%Inst Trans-2.92%
Short Float10.32%EarningsFeb 24/a
Analyst Recom3.75Target Price1.30
Avg Volume3.30M52W Range0.74 - 8.15
Chegg, Inc. engages in providing support and a learning platform for students. Its services include Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, Busuu offerings, Chegg Skills, advertising services, print textbooks, and eTextbooks offerings. The company was founded by Osman Rashid and Aayush Phumbhra on July 29, 2005 and is headquartered in Santa Clara, CA.
PALI - Palisade Bio Inc - Stock Price Chart
TickerPALI [NASD]
CompanyPalisade Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap1.97MEPS (ttm)-15.04
P/E-EPS this Y56.80%
Forward P/E-EPS next Y74.99%
PEG-EPS past 5Y75.28%
P/S-EPS next 5Y52.91%
P/B0.13EPS Q/Q68.50%
Dividend-Sales Q/Q-
Insider Own0.81%Inst Own7.20%
Insider Trans0.00%Inst Trans0.24%
Short Float5.40%EarningsNov 12/b
Analyst Recom1.00Target Price20.00
Avg Volume604.19K52W Range0.75 - 9.65
Mar-14-25 08:30AM Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 (GlobeNewswire) +8.99%
Mar-12-25 08:30AM Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 (GlobeNewswire) +11.70%
Mar-04-25 08:30AM Palisade Bio Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Feb-20-25 08:45AM Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) (GlobeNewswire)
Feb-19-25 09:00AM Palisade Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-10-25 08:45AM Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis (GlobeNewswire) -7.20%
Jan-29-25 08:45AM Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress (GlobeNewswire)
Jan-22-25 08:00AM Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -5.30%
Jan-16-25 08:00AM Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis (GlobeNewswire) -5.68%
Jan-03-25 05:20PM Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.79%
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wei BinxianDirectorNov 21 '24Option Exercise0.003880855Nov 22 04:00 PM
Williams Donald AllenDirectorNov 21 '24Option Exercise0.003880728Nov 22 04:00 PM
Wei BinxianDirectorJun 11 '24Option Exercise0.004650467Jun 12 09:41 PM
Williams Donald AllenDirectorJun 11 '24Option Exercise0.003400340Jun 12 09:40 PM
Jones Mitchell LawrenceChief Medical OfficerMay 28 '24Option Exercise0.004,29004,313May 30 07:44 PM
GTEC - Greenland Technologies Holding Corp - Stock Price Chart
TickerGTEC [NASD]
CompanyGreenland Technologies Holding Corp
CountryUSA
IndustryAuto Parts
Market Cap17.13MEPS (ttm)-0.91
P/E-EPS this Y146.67%
Forward P/E3.07EPS next Y-26.79%
PEG-EPS past 5Y-148.76%
P/S0.20EPS next 5Y-
P/B0.30EPS Q/Q22.97%
Dividend-Sales Q/Q-13.75%
Insider Own47.16%Inst Own12.37%
Insider Trans0.00%Inst Trans17.76%
Short Float0.31%EarningsNov 14/a
Analyst Recom1.00Target Price13.00
Avg Volume200.59K52W Range1.25 - 2.94
Greenland Technologies Holding Corp. engages in the manufacture of drivetrain systems for material handling machineries and electric vehicles, as well as electric industrial vehicles. Its products include the GEF-series electric forklifts, a series of lithium-powered forklifts with three models ranging in size from 1.8 tons to 3.5 tons, and GEL-1800, a 1.8 ton rated load lithium-powered electric wheeled front loader and GEX-8000, an all-electric 8.0 ton rated load lithium-powered wheeled excavator. The company was founded in 2006 and is headquartered in East Windsor, NJ.
CVGI - Commercial Vehicle Group Inc - Stock Price Chart
TickerCVGI [NASD, RUT]
CompanyCommercial Vehicle Group Inc
CountryUSA
IndustryAuto Parts
Market Cap48.84MEPS (ttm)-0.83
P/E-EPS this Y-83.33%
Forward P/E4.86EPS next Y627.27%
PEG-EPS past 5Y-
P/S0.06EPS next 5Y-
P/B0.33EPS Q/Q-266.05%
Dividend-Sales Q/Q-26.80%
Insider Own13.87%Inst Own64.60%
Insider Trans1.16%Inst Trans-5.47%
Short Float3.79%EarningsMar 11/b
Analyst Recom1.00Target Price4.50
Avg Volume359.57K52W Range1.49 - 6.64
Commercial Vehicle Group, Inc. engages in the manufacture, supply, and sale of cab related products and systems. It operates through Vehicle Solutions, Electrical Systems, Aftermarket & Accessories, and Industrial Automation segments. The Vehicle Solutions segment designs, manufactures and sells heavy duty trucks, medium duty trucks, last mile delivery trucks and vans. The Electrical Systems segment engages in the designing, manufacturing and selling cable and harness assemblies for both high and low voltage applications, control boxes, dashboard assemblies and design and engineering for these applications. The Aftermarket & Accessories segment focuses on the designing, manufacturing and selling seats and components sold into the commercial vehicle channels that provide repair and refurbishing. The Industrial Automation segment designs, manufactures and sells warehouse automation subsystems including control panels, electro-mechanical assemblies, cable assemblies, and power and communication solutions. The company was founded in August 2000 and is headquartered in New Albany, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nauman J MichaelDirectorDec 03 '24Buy2.4219,36246,85682,997Dec 04 04:26 PM
Nauman J MichaelDirectorDec 04 '24Buy2.372,8386,72685,835Dec 04 04:26 PM
Nauman J MichaelDirectorDec 02 '24Buy2.402,8006,72063,635Dec 04 04:26 PM
RANCOURT WAYNE MDirectorNov 08 '24Buy2.5815,00038,700157,783Nov 12 04:59 PM
Nauman J MichaelDirectorNov 08 '24Buy2.5010025060,835Nov 12 04:19 PM
AUTL - Autolus Therapeutics plc ADR - Stock Price Chart
TickerAUTL [NASD]
CompanyAutolus Therapeutics plc ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap452.40MEPS (ttm)-0.86
P/E-EPS this Y-2.73%
Forward P/E-EPS next Y18.54%
PEG-EPS past 5Y21.36%
P/S44.70EPS next 5Y28.61%
P/B0.95EPS Q/Q78.10%
Dividend-Sales Q/Q-
Insider Own9.70%Inst Own53.78%
Insider Trans0.00%Inst Trans-7.79%
Short Float3.79%EarningsMar 20/b
Analyst Recom1.00Target Price9.99
Avg Volume1.27M52W Range1.66 - 6.60
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin PuleOfficerSep 16 '24Proposed Sale4.23698,7412,955,674Sep 16 05:02 PM
FMTO - Femto Technologies Inc - Stock Price Chart
TickerFMTO [NASD]
CompanyFemto Technologies Inc
CountryIsrael
IndustrySoftware - Application
Market Cap1.06MEPS (ttm)-105.93
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-90.50%
P/S1.41EPS next 5Y-
P/B0.49EPS Q/Q-17.39%
Dividend-Sales Q/Q-50.55%
Insider Own11.82%Inst Own9.23%
Insider Trans0.00%Inst Trans0.84%
Short Float0.49%Earnings-
Analyst Recom-Target Price-
Avg Volume707.35K52W Range1.67 - 69.12
Femto Technologies, Inc. develops, markets and sells a proprietary client relationship management software known as Benefit CRM and Cannabis CRM platform. It also develops the EZ-G device, a patent-pending device that, combined with proprietary software. The company was founded on March 29, 2021 and is headquartered in Kiryat Motzkin, Israel.
MRSN - Mersana Therapeutics Inc - Stock Price Chart
TickerMRSN [NASD, RUT]
CompanyMersana Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap53.02MEPS (ttm)-0.57
P/E-EPS this Y-29.24%
Forward P/E-EPS next Y6.04%
PEG-EPS past 5Y2.74%
P/S1.31EPS next 5Y-13.09%
P/B-EPS Q/Q29.51%
Dividend-Sales Q/Q52.89%
Insider Own31.15%Inst Own54.62%
Insider Trans-0.38%Inst Trans-16.44%
Short Float12.02%EarningsMar 03/b
Analyst Recom1.22Target Price4.71
Avg Volume5.68M52W Range0.43 - 5.11
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mandelia AshishVP, Chief Accounting OfficerJan 15 '25Option Exercise0.008,685061,073Jan 17 07:27 PM
Mandelia AshishVP, Chief Accounting OfficerJan 16 '25Sale0.583,5542,06157,519Jan 17 07:27 PM
Protopapas AnnaDirectorJan 15 '25Option Exercise0.0021,2500176,678Jan 17 07:26 PM
Protopapas AnnaDirectorJan 16 '25Sale0.588,6375,009168,041Jan 17 07:26 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 15 '25Option Exercise0.0019,7910265,721Jan 17 07:25 PM
1234567891020